PYXS — Pyxis Oncology Income Statement
0.000.00%
Last trade - 00:00
- $204.93m
- $47.90m
- 40
- 21
- 64
- 37
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 2.88 | 12.9 | 69.7 | 123 | 82.2 |
Operating Profit | -2.88 | -12.9 | -69.7 | -123 | -82.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.77 | -12.8 | -76 | -121 | -73.8 |
Net Income After Taxes | -2.77 | -12.8 | -76 | -121 | -73.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.77 | -12.8 | -76 | -121 | -73.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.77 | -12.8 | -76 | -121 | -73.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.085 | -0.392 | -2.36 | -3.65 | -1.85 |
Dividends per Share |